Clinical trials: Multiple Comorbidity, open to volunteers
Interstitial Lung Disease, Comorbidities and Coexisting Conditions
Taiwan Interstitial Lung Disease Multi-center Investigation and Registry
The Taiwan Interstitial Lung Disease (ILD) Multi-center Investigation and Registry aims to evaluate the long-term outcomes of patients with fibrotic interstitial lung disease.
- Conditions
- Interstitial Lung Disease, Comorbidities and Coexisting Conditions, Pulmonary Arterial Hypertension, Treatment Adherence
- Trial name
- TAILI (NCT06476470)
- Where
- Taiwan
- Volunteers
- 10,000 people
- Sponsor
- Taichung Veterans General Hospital
Obesity & Overweight, Diabetes Mellitus, Type 2
Chinese Overweight/Obesity Cohort: Metabolic & Comorbidity Risks
This is a nationwide, multi-center, long-term follow-up study of overweight and obese adults in China. The study aims to recruit approximately 26,000 participants across 39 hospitals to better understand how body weight affects…
- Conditions
- Obesity & Overweight, Diabetes Mellitus, Type 2, Hypertension, Non-alcoholic Fatty Liver Disease (MASLD)
- Trial name
- NCT07884903
- Testing
- No intervention; observational assessment only
- Where
- China
- Volunteers
- 25,974 people
- Sponsor
- Shanxi Bethune Hospital
Obesity, Overweight
Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)
Study GSBR-1290-12 is a Phase 3 pivotal, multicenter, global, randomized, placebo-controlled, double-blind study to investigate the long-term efficacy, safety, and tolerability of 3 maintenance doses of aleniglipron once daily…
- Conditions
- Obesity, Overweight, Chronic Weight Management
- Trial name
- NCT07654361
- Testing
- Aleniglipron
- Where
- 71 sites in United States
- Volunteers
- 3,600 people
- Sponsor
- Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
Functional Neurological Disorders, Multiple Sclerosis
Assessment of the Frequency of Functional Neurological Disorders in Multiple Sclerosis and Analysis of Clinical and Psychological Determinants
Multiple sclerosis (MS) and functional neurological disorders (FND) share clinical features, which may result in FND being overlooked in patients with MS.
- Trial name
- FTNF-SEP (NCT07849816)
- Volunteers
- 100 people
- Sponsor
- University Hospital, Strasbourg, France
MASH - Metabolic Dysfunction-Associated Steatohepatitis
Rezdiffra® With Concomitant Therapies Commonly Used to Treat Comorbidities in Adults With MASH and F2-F3 Fibrosis
To determine the safety of Rezdiffra (Resmetirom) when administered alongside common prescriptions for Diabetes Metellus (Farxiga/dapagliflozin \& Actos/pioglitazone)
- Trial name
- NCT07848191
- Testing
- Rezdiffra, Resmetirom, ACTOS/pioglitazone
- Where
- 16 sites in United States
- Volunteers
- 150 people
- Sponsor
- Madrigal Pharmaceuticals, Inc.
Cardiometabolic Comorbidities
Self-management Intervention for People With Cardiometabolic Multimorbidity: A Pilot Randomized Controlled Trial
This pilot randomized controlled trial aims to evaluate the feasibility and preliminary effects of a telephone-based self-management intervention for adults with cardiometabolic multimorbidity.
- Trial name
- NCT07792785
- Testing
- Motivational interviewing, self-affirmation and problem-solving, Usual Care
- Where
- China
- Volunteers
- 72 people
- Sponsor
- The Hong Kong Polytechnic University
Down Syndrome, Intellectual Disability
Genetic Markers and Biomarkers in Patients With Intellectual Disabilities of Genetic Origin
Analyze genetic and biological markers in patients with Intellectual Deficiencies (ID) of genetic origin in order to better understand the mechanisms of modified genes, cellular mechanisms, pathways involved in different…
- Trial name
- BioJeL (NCT05767203)
- Testing
- Biological samplings
- Where
- France
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- Institut Jerome Lejeune
Cardiovascular, Comorbidity
Improving Patient-Centered Care for Underserved Older African American Patients With Cardiovascular Comorbidities
This is formative evaluation trial guided by the Values Clarification Theory25 and the Cultural Values Theory26, with specific aims to: Aim 1.
- Conditions
- Cardiovascular, Comorbidity, Diabetes, Inflammatory Joint Diseases
- Trial name
- PPC Heart (NCT07748858)
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- University of Alabama at Birmingham
NAFLD, Obesity, Morbid
Integrated Multi-omics Data for Personalized Treatment of Obesity-associated Fatty Liver Disease
The investigators seek to analyze the samples provided by patients with obesity-associated fatty liver disease at the multi-omics level and to integrate the results with clinical information, genotypic variants, and factors…
- Conditions
- NAFLD, Obesity, Morbid, Comorbidities and Coexisting Conditions
- Trial name
- NCT05554224
- Testing
- To propose diagnostic tests for liver diseases before surgical decisions.
- Where
- Spain
- Volunteers
- 1,104 people
- Sponsor
- Institut Investigacio Sanitaria Pere Virgili
Post-stroke, Parkinson Disease
Evaluation of the Impact of Virtual Park on Training Motivation in Adult Patients
The purpose of this clinical study is to evaluate the feasibility, usability, and motivational impact of VirtualPark, a virtual reality-based dual-task rehabilitation system, in adults with neurological and age-related…
- Conditions
- Post-stroke, Parkinson Disease, Amyotrophic Lateral Sclerosis, Mild Cognitive Impairment (MCI)
- Trial name
- VP_Adults (NCT07616050)
- Testing
- Dual-task training with Virtual Reality, Cycling training
- Where
- 7 sites in Italy
- Volunteers
- 70 people
- Sponsor
- Marta Mondellini
Drug Interactions, Primary Prevention
LDL-C Optimization Using Inclisiran in Patients in Which Drug-Drug Interactions Limit LDL Lowering
Drug-drug interactions often limit statin optimization in a population of patients prescribed cytochrome P3A4 inhibitors, which include immunosuppressive agents, protease inhibitors, and antifungals.
- Conditions
- Drug Interactions, Primary Prevention, Cardiometabolic Syndrome, LDL-Cholersterol Lowering
- Trial name
- SOLVE-LDL-C (NCT06865885)
- Testing
- Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- University of California, San Diego